PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix

Cisplatin is a keystone for treatment of both recurring and locally advanced cervical cancer. However toxic side effects and acquired resistance limits its efficacy. Enhanced DNA repair is one of the mechanisms through which cancer cells acquire cisplatin resistance. Inhibitors of PARP, which is a D...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Minakshi, Kumar, Sachin, Sharma, Ashok, Chauhan, Shyam S., Bhatla, Neerja, Kumar, Sunesh, Bakhshi, Sameer, Gupta, Ritu, Kumar, Lalit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611509/
https://www.ncbi.nlm.nih.gov/pubmed/31303961
http://dx.doi.org/10.18632/oncotarget.27008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611509/
https://www.ncbi.nlm.nih.gov/pubmed/31303961
http://dx.doi.org/10.18632/oncotarget.27008

Ejemplares similares